Dr. Mark D. Sanchez, M.D.
Fertility (Reproductive Endocrinology) (Reproductive Endocrinology Physician)
At a glance
- Medical school
- University of Florida College of Medicine (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2005
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: University of Florida College of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Reproductive Endocrinology Physician primary
FL license ME 71673 -
Gynecology Physician
FL license ME 71673 -
Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) Physician
FL license ME 71673
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Fertility (Reproductive Endocrinology) per capita by county →
Where they work
Medical groups
- Ohi West Medical Group LLC (202 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 4 companies reported 9 payments worth $2,194 in total to this clinician.
| Luye Pharma (USA) LTD. | $2,000 |
|---|---|
| Organon LLC | $94.87 |
| Ferring Pharmaceuticals Inc. | $85.21 |
| Hologic Sales and Service, LLC | $14.11 |
| Consulting Fee | $2,000 |
|---|---|
| Food and Beverage | $194 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Luye Pharma (USA) LTD. Nov 25, 2025 | Consulting Fee ERZOFRI EXTENDED-RELEASE · Treatment of schizophrenia and schizoaffective disorder in adults | $2,000 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $321,395 in research payments for these studies, mostly to the institutions running them.
- PROGRESS - Subcutaneous PROgesterone in fRozen-thawed single Euploid blaStocyst tranSfer
Ibsa Institut Biochimique SA - Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females
Exeltis, USA Inc. · Completed · NCT05461573
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.